Incorporating hematopoietic growth factors into chemotherapy regimens is a common method for mitigating toxicity of dose-intensive regimens. A clinical trial has shown that G-CSF can counteract acute toxicities, permitting further dose intensification of induction chemotherapy. However, the effects of these strategies on long-term toxicities and overall survival remain undefined.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cohn, S. L. et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 27, 289–297 (2009).
American Academy of Pediatrics Section on Hematology/Oncology Children's Oncology Group. Long-term follow-up care for pediatric cancer survivors. Pediatrics 123, 906–915 (2009).
Ladenstein, R. et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J. Clin. Oncol. 28, 3516–3524 (2010).
Pearson, A. D. et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 9, 247–256 (2008).
Hansford, L. M. et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc. Natl Acad. Sci. USA 101, 12664–12669 (2004).
Song, L. et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest. 119, 1524–1536 (2009).
Kim, E. & Shohet, J. Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis. J. Natl Cancer Inst. 101, 1527–1529 (2009).
Kushner, B. H. et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J. Clin. Oncol. 22, 4888–4892 (2004).
Valteau-Couanet, D. et al. Results of induction chemotherapy in children older than 1 year with stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) Protocol. J. Clin. Oncol. 23, 532–540 (2005).
Matthay, K. K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165–1173 (1999).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Russell, H., Shohet, J. G-CSF counteracts chemotherapy toxicity in neuroblastoma. Nat Rev Clin Oncol 8, 6–8 (2011). https://doi.org/10.1038/nrclinonc.2010.195
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.195
